Literature DB >> 10590121

Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

K Salzwedel1, E D Smith, B Dey, E A Berger.   

Abstract

We devised an experimental system to examine sequential events by which the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) interacts with CD4 and coreceptor to induce membrane fusion. Recombinant soluble CD4 (sCD4) activated fusion between effector cells expressing Env and target cells expressing coreceptor (CCR5 or CXCR4) but lacking CD4. sCD4-activated fusion was dose dependent, occurred comparably with two- and four-domain proteins, and demonstrated Env-coreceptor specificities parallel to those reported in conventional fusion and infectivity systems. Fusion activation occurred upon sCD4 preincubation and washing of the Env-expressing effector cells but not the coreceptor-bearing target cells, thereby demonstrating that sCD4 exerts its effects by acting on Env. These findings provide direct functional evidence for a sequential two-step model of Env-receptor interactions, whereby gp120 binds first to CD4 and becomes activated for subsequent functional interaction with coreceptor, leading to membrane fusion. We used the sCD4-activated system to explore neutralization by the anti-gp120 human monoclonal antibodies 17b and 48d. These antibodies reportedly bind conserved CD4-induced epitopes involved in coreceptor interactions but neutralize HIV-1 infection only weakly. We found that 17b and 48d had minimal effects in the standard cell fusion system using target cells expressing both CD4 and coreceptor but potently blocked sCD4-activated fusion with target cells expressing coreceptor alone. Both antibodies strongly inhibited sCD4-activated fusion by Envs from genetically diverse HIV-1 isolates. Thus, the sCD4-activated system reveals conserved Env-blocking epitopes that are masked in native Env and hence not readily detected by conventional systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590121      PMCID: PMC111543          DOI: 10.1128/jvi.74.1.326-333.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  HIV and SIV gp120 binding does not predict coreceptor function.

Authors:  S S Baik; R W Doms; B J Doranz
Journal:  Virology       Date:  1999-07-05       Impact factor: 3.616

2.  Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.

Authors:  P R Clapham; A McKnight; R A Weiss
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

Authors:  J P Moore; H Yoshiyama; D D Ho; J E Robinson; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

Review 4.  Receptor-mediated activation of the viral envelope and viral entry.

Authors:  J S Allan
Journal:  AIDS       Date:  1993       Impact factor: 4.177

5.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains.

Authors:  J P Moore; Q J Sattentau; H Yoshiyama; M Thali; M Charles; N Sullivan; S W Poon; M S Fung; F Traincard; M Pinkus
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

7.  Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.

Authors:  M Thali; M Charles; C Furman; L Cavacini; M Posner; J Robinson; J Sodroski
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

Authors:  O Nussbaum; C C Broder; E A Berger
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Enhancement of SIV infection with soluble receptor molecules.

Authors:  J S Allan; J Strauss; D W Buck
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

10.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

View more
  58 in total

Review 1.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

2.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.

Authors:  Ming Li; Jesus F Salazar-Gonzalez; Cynthia A Derdeyn; Lynn Morris; Carolyn Williamson; James E Robinson; Julie M Decker; Yingying Li; Maria G Salazar; Victoria R Polonis; Koleka Mlisana; Salim Abdool Karim; Kunxue Hong; Kelli M Greene; Miroslawa Bilska; Jintao Zhou; Susan Allen; Elwyn Chomba; Joseph Mulenga; Cheswa Vwalika; Feng Gao; Ming Zhang; Bette T M Korber; Eric Hunter; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

5.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.

Authors:  Johannes Brozy; Erika Schlaepfer; Markus Muenz; Roberto F Speck; Christina K S Mueller; Mary-Aude Rochat; Silvana K Rampini; Renier Myburgh; Tobias Raum; Peter Kufer; Patrick A Baeuerle
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

7.  Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4.

Authors:  Theresa L-Y Chang; Chia-Hwa Chang; David A Simpson; Qiang Xu; Patrick K Martin; Laurel A Lagenaur; Gary K Schoolnik; David D Ho; Sharon L Hillier; Mark Holodniy; John A Lewicki; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-12       Impact factor: 11.205

8.  Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion.

Authors:  C M Finnegan; W Berg; G K Lewis; A L DeVico
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

10.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.